title: Fate alteration of neuroepithelial cells from neurogenesis to astrocytogenesis by bone morphogenetic proteins.
abstract: Bone morphogenetic proteins (BMPs), a class of cytokines belonging to the transforming growth factor-beta superfamily, have been shown to play a wide variety of roles during development including those in the central nervous system. We here report that BMP2, BMP4 and BMP7 have an equivalent potential to inhibit neurogenesis and concomitantly induce astrocytogenesis of mouse fetal neuroepithelial cells. We further show that these BMPs activate a promoter of the gene for negative helix-loop-helix (HLH) factor, Id1, which is known to inhibit the function of such neurogenic transcription factors as Mash1 and neurogenin. These results suggest that BMP2, BMP4 and BMP7 alternate the fate of neuroepithelial cells from neuronal type to astrocytic one via a common mechanism involving negative HLH factor.
authors.affiliation: Department of Cell Fate Modulation, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1, Honjo, Kumamoto 860-0811, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yanagisawa
authors.forename: T
authors.initials: T
authors.lastname: Takizawa
authors.forename: W
authors.initials: W
authors.lastname: Ochiai
authors.forename: A
authors.initials: A
authors.lastname: Uemura
authors.forename: K
authors.initials: K
authors.lastname: Nakashima
authors.forename: T
authors.initials: T
authors.lastname: Taga
mesh_terms: D030201:Activin Receptors, Type I / Q000096:biosynthesis / Q000235:genetics; D000818:Animals; D001253:Astrocytes / Q000166:cytology*; D055396:Bone Morphogenetic Protein 2; D055415:Bone Morphogenetic Protein 4; D055419:Bone Morphogenetic Protein 7; D052005:Bone Morphogenetic Protein Receptors, Type I; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology* / Q000502:physiology; D019070:Cell Lineage / Q000187:drug effects*; D004268:DNA-Binding Proteins / Q000235:genetics; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects*; D005904:Glial Fibrillary Acidic Protein / Q000235:genetics; D018257:Helix-Loop-Helix Motifs; D051798:Inhibitor of Differentiation Protein 1; D051379:Mice; D008813:Mice, Inbred ICR; D009419:Nerve Tissue Proteins / Q000235:genetics; D009474:Neurons / Q000166:cytology*; D011247:Pregnancy; D011401:Promoter Regions, Genetic / Q000235:genetics; D017346:Protein Serine-Threonine Kinases; D011506:Proteins; D017978:Receptors, Growth Factor; D012097:Repressor Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013687:Telencephalon / Q000166:cytology* / Q000196:embryology; D014157:Transcription Factors / Q000235:genetics; D016212:Transforming Growth Factor beta
chemical_list: C525719:Bmp2 protein, mouse; C525810:Bmp4 protein, mouse; D055396:Bone Morphogenetic Protein 2; D055415:Bone Morphogenetic Protein 4; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D004268:DNA-Binding Proteins; D005904:Glial Fibrillary Acidic Protein; C497455:Idb1 protein, mouse; D051798:Inhibitor of Differentiation Protein 1; D009419:Nerve Tissue Proteins; D011506:Proteins; D017978:Receptors, Growth Factor; D012097:Repressor Proteins; D014157:Transcription Factors; D016212:Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D030201:Activin Receptors, Type I; D052005:Bone Morphogenetic Protein Receptors, Type I